The study postulates that the qualitative shift in AAT glycoforms is an attempt to trigger antielastase activity and boost the anti-inflammatory response [123], as has been reported in patients with community-acquired pneumonia [17], but unfortunately this appears futile as this modification appears to correlate with negative outcomes in COVID-19. The gene discussed is SERPINA1; the disease is COVID-19.